MGMT, O-6-methylguanine-DNA methyltransferase, 4255

N. diseases: 444; N. variants: 24
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0334588
Disease: Giant Cell Glioblastoma
Giant Cell Glioblastoma
0.510 GeneticVariation disease BEFREE Our data indicate, that in addition to the histological and immunohistochemical evaluation, investigation of MGMT promoter methylation and in particular BRAF V600E mutations represent reliable additional tools to sustain differentiation of gcGBM from PXA on a molecular basis. 27253461 2016
CUI: C0334588
Disease: Giant Cell Glioblastoma
Giant Cell Glioblastoma
0.510 Biomarker disease ORPHANET A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma. 22380407 2012
CUI: C0334588
Disease: Giant Cell Glioblastoma
Giant Cell Glioblastoma
0.510 Biomarker disease CTD_human Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. 22162573 2012
CUI: C0334588
Disease: Giant Cell Glioblastoma
Giant Cell Glioblastoma
0.510 Biomarker disease ORPHANET O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications. 20556478 2011
CUI: C0334588
Disease: Giant Cell Glioblastoma
Giant Cell Glioblastoma
0.510 Biomarker disease CTD_human MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. 20131314 2010
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 PosttranslationalModification group BEFREE Since new diagnostic methods such as methylome-based classification of brain tumors are more and more frequently performed, we aimed at comparing the suitability of calculating the MGMT promoter methylation status in a quantitative manner from the methylome profiling as compared to the classic gold standard assessment by PCR. 31784096 2020
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 PosttranslationalModification disease BEFREE MGMT promoter hypermethylation was detected in 38.7% of glioblastoma patients. 31701343 2020
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 PosttranslationalModification disease BEFREE The CpG methylation status of the MGMT promoter strongly correlates with clinical outcome and, therefore, is used as prognostic marker during glioblastoma therapy. 31395346 2020
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression disease BEFREE Here, we quantify baseline expression of MGMT and EGFR protein in newly diagnosed GBM samples using mass spectrometry. 31823165 2020
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 PosttranslationalModification disease BEFREE The results confirm that the quantitative level of MGMT promoter methylation is a positive prognostic factor in newly diagnosed patients with GBM. 31422371 2020
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 GeneticVariation disease BEFREE Histological examination confirmed a wild-type (WT) IDH1/2, MGMT (DNA repair enzyme O6-methylguanine-DNA methyltransferase) methylated glioblastoma with a proliferative index focally as high as 20%. 31173153 2020
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 PosttranslationalModification disease BEFREE MGMT methylation appears to convey a survival benefit in the setting of bevacizumab treatment for progressive GBM. 31756059 2020
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 PosttranslationalModification disease BEFREE In addition to its benefits for molecular subgrouping and copy number analysis of brain tumors, DNA-methylation based classification is a highly reliable tool for the assessment of MGMT promoter methylation status in glioblastoma patients. 31784096 2020
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 PosttranslationalModification disease BEFREE • ASL-PWI can aid to predict IDH and MGMT promoter methylation statuses in GBM. 31468161 2020
CUI: C0017638
Disease: Glioma
Glioma
0.400 PosttranslationalModification disease BEFREE <i>O</i>(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation is a high predictive factor for therapy results of temozolomide in patients with glioma. 31422371 2020
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 PosttranslationalModification disease BEFREE MGMT methylation appears to convey a survival benefit in the setting of bevacizumab treatment for progressive GBM. 31756059 2020
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 PosttranslationalModification disease BEFREE In addition to its benefits for molecular subgrouping and copy number analysis of brain tumors, DNA-methylation based classification is a highly reliable tool for the assessment of MGMT promoter methylation status in glioblastoma patients. 31784096 2020
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 PosttranslationalModification disease BEFREE The results confirm that the quantitative level of MGMT promoter methylation is a positive prognostic factor in newly diagnosed patients with GBM. 31422371 2020
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 PosttranslationalModification disease BEFREE Some of these genetic alterations are currently believed to have clinical significance and are more related to secondary GBMs: TP53 mutations, detectable in the early stages of secondary GBM (found in 65%), isocitrate dehydrogenase 1/2 mutations (50% of secondary GBMs), and also O6-methylguanine-DNA methyltransferase promoter methylation (75% of secondary GBMs). 31550738 2020
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 PosttranslationalModification disease BEFREE The CpG methylation status of the MGMT promoter strongly correlates with clinical outcome and, therefore, is used as prognostic marker during glioblastoma therapy. 31395346 2020
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 AlteredExpression disease BEFREE Here, we quantify baseline expression of MGMT and EGFR protein in newly diagnosed GBM samples using mass spectrometry. 31823165 2020
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 PosttranslationalModification disease BEFREE • ASL-PWI can aid to predict IDH and MGMT promoter methylation statuses in GBM. 31468161 2020
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 GeneticVariation disease BEFREE Histological examination confirmed a wild-type (WT) IDH1/2, MGMT (DNA repair enzyme O6-methylguanine-DNA methyltransferase) methylated glioblastoma with a proliferative index focally as high as 20%. 31173153 2020
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.400 PosttranslationalModification disease BEFREE MGMT promoter hypermethylation was detected in 38.7% of glioblastoma patients. 31701343 2020
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.400 AlteredExpression group BEFREE Disulfiram has also been shown to inhibit the proteasomes, DNA topoisomerases, DNA methyltransferase, glutathione S-transferase P1, and O6- methylguanine DNA methyltransferase, a DNA repair protein highly expressed in brain tumors. 31084595 2019